To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7599158.
Chronic venous disease (CVD) is widespread, underdiagnosed, and can progress to chronic venous insufficiency and venous ulcers, which can require extensive treatment and hospitalization. These conditions negatively impact patient quality of life and place substantial burdens on healthcare resources. The two main risk factors for CVD are age and obesity. Thus, with the growing prevalence of obesity and the increasing longevity of the population, the burden of CVD is expected to increase dramatically in the coming decades. Appropriate lifestyle changes and care, which may include treatment with venoactive drugs, can slow disease progression, improve quality of life, and are likely to reduce healthcare costs. Physicians should be aware of this growing problem and of the effective treatments available for CVD. We recommend the accompanying short summaries from a symposium held at the recent European Venous Forum as a means for our colleagues to learn more about the burden and suffering associated with CVD.
Evans CJ, Fowkes FG, Ruckley CV, Lee AJ. Prevalence of varicose veins and chronic venous insufficiency in men and women in the general population: Edinburgh Vein Study. J Epidemiol Commun Health. 1999;53(3):149–53 (Epub 1999/07/09). CrossRef
Laing W. Chronic venous diseases of the leg. London: Office of Health Economics; 1992.
Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–15 (Epub 2012/04/03).
Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N. Burden of venous leg ulcers in the United States. J Med Econ. 2014;17(5):347–56 (Epub 2014/03/15). CrossRef
Office for National Statistics. National Population Projections: 2016-based statistical bulletin. In: Statistics OfN, editor. London: Office for National Statistics; 2016.
Brand FN, Dannenberg AL, Abbott RD, Kannel WB. The epidemiology of varicose veins: the Framingham Study. Am J Prev Med. 1988;4(2):96–101 (Epub 1988/03/01). CrossRef
Lee AJ, Robertson LA, Boghossian SM, Allan PL, Ruckley CV, Fowkes FG, et al. Progression of varicose veins and chronic venous insufficiency in the general population in the Edinburgh Vein Study. J Vasc Surg Venous Lymphat Disord. 2015;3(1):18–26 (Epub 2015/01/01). CrossRef
Pannier F, Rabe E. The relevance of the natural history of varicose veins and refunded care. Phlebology. 2012;27(Suppl 1):23–6 (Epub 2012/02/15). CrossRef
Pannier F, Rabe E. Progression in venous pathology. Phlebology. 2015;30(1 Suppl):95–7 (Epub 2015/03/03). CrossRef
Onida S, Davies AH. Predicted burden of venous disease. Phlebology. 2016;31(1 Suppl):74–9 (Epub 2016/02/27). CrossRef
Bush RG, Bush P, Flanagan J, et al. Factors associated with recurrence of varicose veins after thermal ablation: results of the recurrent veins after thermal ablation study. ScientificWorldJournal. 2014;2014:505843 (Epub 2014/03/05). CrossRef
O’Donnell TF, Balk EM, Dermody M, Tangney E, Iafrati MD. Recurrence of varicose veins after endovenous ablation of the great saphenous vein in randomized trials. J Vasc Surg Venous Lymphat Disord. 2016;4(1):97–105 (Epub 2016/03/08). CrossRef
Rabe E, Pannier F, Ko A, Berboth G, Hoffmann B, Hertel S. Incidence of varicose veins, chronic venous insufficiency, and progression of the disease in the Bonn Vein Study II. J Vasc Surg. 2010;51(3):791. CrossRef
Nicolaides A, Kakkos S, Baekgaard N, et al. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Part I. Int Angiol. 2018;37(3):181–254 (Epub 2018/06/07). PubMed
Palfreyman SJ, Michaels JA. A systematic review of compression hosiery for uncomplicated varicose veins. Phlebology. 2009;24(Suppl 1):13–33 (Epub 2009/05/16). CrossRef
das Graças C de Souza M, Cyrino FZ, de Carvalho JJ, Blanc-Guillemaud V, Bouskela E. Protective effects of micronized purified flavonoid fraction (MPFF) on a novel experimental model of chronic venous hypertension. Eur J Vasc Endovasc Surg. 2018;55(5):694–702 (Epub 2018/03/29). CrossRef
Kirienko A, Radak D. Clinical acceptability study of once-daily versus twice-daily micronized purified flavonoid fraction in patients with symptomatic chronic venous disease: a randomized controlled trial. Int Angiol. 2016;35(4):399–405 (Epub 2015/11/19). PubMed
Carpentier P, van Bellen B, Karetova D, et al. Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial. Int Angiol. 2017;36(5):402–9 (Epub 2017/02/17). PubMed
- Burden and Suffering in Chronic Venous Disease
Andrew N. Nicolaides
- Springer Healthcare
Advances in Therapy
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II